| Autor: |
Lyseng-Williamson, Katherine, McCormack, Paul, Kim, Esther |
| Předmět: |
|
| Zdroj: |
Drugs & Therapy Perspectives; Mar2016, Vol. 32 Issue 3, p91-97, 7p |
| Abstrakt: |
Icosapent ethyl (Vascepa) is a high-purity ethyl ester of eicosapentaenoic acid (EPA), a long-chain omega-3 fatty acid associated with plasma triglyceride lowering. It does not contain the omega-3 fatty acid docosahexaenoic acid (DHA) that has been associated with increased low-density lipoprotein cholesterol (LDL-C) levels. Oral icosapent ethyl 2 g twice daily is approved in the USA for use as an adjunct to diet in lowering triglyceride levels in adult patients with severe hypertriglyceridaemia [triglyceride ≥500 mg/dL (≥5.65 mmol/L)]. In clinical trials in patients with very high or high triglyceride levels, icosapent ethyl 4 g/day significantly reduced triglyceride levels and other lipid parameters without increasing LDL-C levels, reduced levels of circulating markers of inflammation and was well tolerated. Case reports suggest that switching patients to icosapent ethyl from other omega-3 fatty acid products may improve lipid parameters. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink